^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
PROGENSA PCA3 Assay

Company:
Hologic
Type:
FDA Approved
Related tests:

Details

Evidence
The PROGENSA PCA3 Assay is an in vitro nucleic acid amplification test. The assay measures the concentration of prostate cancer gene 3 (PCA3) and prostate-specific antigen (PSA) RNA molecules and calculates the ratio of PCA3 RNA molecules to PSA RNA molecules (PCA3 Score) in post-digital rectal exam (DRE) first-catch male urine specimens. The PROGENSA PCA3 Assay is indicated for use in conjunction with other patient information to aid in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies and for whom a repeat biopsy would be recommended by a urologist based on current standard of care, before consideration of PROGENSA PCA3 Assay results.
Cancer:
Prostate Cancer
Gene:
PCA3 (Prostate cancer associated 3)
Method:
Nucleic acid amplification / PCR
Approvals
Date
Cancer
Gene
Drug
By
09/30/06
CE
02/13/12
FDA
Confirmatory trial(s)